A major scientific publication
Development of an onco-therapeutic vaccine candidate against human papillomavirus (HPV)-induced cancers, based on preclinical results showing 100% efficacy
The Biotech TheraVectys, in collaboration with Institut Pasteur, has just demonstrated the preclinical efficacy of its “Lenti-HPV-07” lentiviral vector-based vaccine candidate, administered intramuscularly, against cervical and oropharyngeal cancers induced by human papillomavirus (HPV).
These results were published in EMBO Molecular Medicine journal in an article entitled “Full eradication of pre-clinical human papilloma virusinduced tumors by a lentiviral vaccine”.
Prophylactic and therapeutic vaccination
There is a globally unmet and critical need to prevent and treat infectious disease and cancer.
We support patients and healthcare providers by developing prophylactic and therapeutic
immunotherapies across a diverse pipeline, covering:
Thanks to our highly effective proprietary technology platform,
we have several investigational therapies already progressing through clinical trials.